Cancer

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage…

2 months ago

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to…

2 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…

2 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused…

2 months ago

Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering…

2 months ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025…

2 months ago

Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated…

2 months ago

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct.…

2 months ago

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs…

2 months ago

The Lustgarten Foundation Gathered Nation’s Foremost Pancreatic Cancer Experts for Annual Scientific Advisory Board Meeting

COLD SPRING HARBOR, N.Y., Oct. 15, 2025 /PRNewswire/ -- The Lustgarten Foundation, the world's largest private funder of pancreatic cancer…

2 months ago